Professor Emil Lou from the University of Minnesota recently highlighted a significant study published in Cell Reports Medicine, exploring how sex-biased intratumoral microbiomes affect tumor biology and treatment outcomes. Led by Dr. Yuting Shan, this research evaluated over 5,000 tumors and identified distinct microbial taxa associated with male and female patients, revealing their differing impacts on estrogen and immune pathways. The findings suggest that these microbiome differences may influence drug responses and patient survival rates. The study was supported by the NIH’s Translational Research Development Program, emphasizing its role in early-stage cancer research.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://oncodaily.com/voices/emil-lou-490318
